Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide - Test2 - elhamkhani - TriplyDB

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

http://www.wikidata.org/entity/Q35505839

about

Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies Modern approaches to HLA-haploidentical blood or marrow transplantation Alternative Donor Transplantation for Acute Myeloid Leukemia Alternative donor transplant of benign primary hematologic disorders HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene Haplo is the new black.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Haploidentical transplantation for hematologic malignancies: where do we stand?Overview of the progress on haploidentical hematopoietic transplantation.Emerging concepts in haematopoietic cell transplantation.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Survival of neural progenitors allografted into the CNS of immunocompetent recipients is highly dependent on transplantation site.Are alternative donors really still "alternative?".Alternative donor SCT for the treatment of MHC class II deficiency.Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Advances in haploidentical stem cell transplantation for hematologic malignancies.Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation.

P2860

Q26745527-A38052A2-55FE-46F0-BA3D-D4533E9A1F83 Q26797506-2B623E44-99F6-49A6-9B63-825D25A04D0A Q26799456-E2995A7E-386A-4C4C-8621-EA0D7419B90F Q26823398-39283771-49FE-4BCF-B130-8117B79B4F2B Q33566388-8314EAA6-D395-4CAE-B3D9-E424275C6580 Q33608520-16148FF5-51B9-489B-A677-1CAAF8E20EDA Q33781162-CC6ED9B0-4CB1-40CF-A65D-52055C982EE4 Q33987066-183A8870-38DB-4712-87F5-CA5268AE511A Q34684038-2CD96558-FC5E-4D42-943D-CA8EA687D680 Q35784529-469D7326-65E8-4721-AA5E-2C9D7C02FB6C Q36264895-DBDB2F3B-7506-4FB4-BB02-2291A0C16E22 Q36724916-B407D911-0EC4-4F8E-B641-8F9330B59BC5 Q36854831-6BD15C61-6249-41E4-8894-9B91C4DA7040 Q37522577-853451C3-2460-4F19-9463-B8B0F28133BE Q38013047-AF0F7AC5-D5EE-4CD1-8318-73F74372C4B2 Q38066860-14678F2E-E6F3-466B-AD51-053078C08735 Q39230205-C901F514-BDBD-4AF2-B961-51C74B6B3602 Q41185627-DD072934-75AC-46B0-BB93-855070A212CC Q45698973-3122E34F-DB65-4A60-A347-3A46A7F762BE Q45795174-F4F848C9-6730-4071-A42C-47D5A6353D89 Q51636737-34226D69-0CE3-4614-A925-635F3000085E Q52804937-BCE69EB2-34A5-4E65-AB8F-A185AE7233CD

P2860

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

http://www.wikidata.org/entity/Q35505839

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@ast

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@en

type

label

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@ast

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@en

prefLabel

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@ast

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@en

P1433

Q35505839-47AE3309-1D76-4030-A738-43E616CD33FA

P1476

Q35505839-B81410AF-E17D-4186-84EF-B9FB42B4A3F0

P2093

Q35505839-36176DE5-3165-4008-81C7-896CF64FB5F7

Q35505839-9027521B-2466-4175-8AE4-7A0D1CDE852A

Q35505839-AF74FAD1-BF02-4446-B15F-6A0D746E5A46

Q35505839-B8A10966-AEEA-44C2-9D8C-3C4B9A89BED1

Q35505839-BDA4AEC0-60E0-4E4C-8188-9E9CE901ADE0

Q35505839-C14768C2-EF98-4227-9A30-B383E9459231

Q35505839-C1AA7510-DA49-4E90-9561-A83410AB195F

P2860

Q35505839-22AAF70A-7F7D-4DB6-9CDD-9D9AC23BCE90

Q35505839-2B2A2BB2-45D6-4516-85D8-60EA17647E06

Q35505839-31D497DC-ED72-41B0-94E1-9FA317894E5D

Q35505839-3EF72A1D-9298-4103-863C-532AFE13A052

Q35505839-4BF0B679-57A9-419D-90EF-67054F169A18

Q35505839-64C8AABF-343E-47B7-91DE-90727341FB03

Q35505839-69345DA2-581B-48DA-AFC1-A917A9F07886

Q35505839-7DB6EEB3-AC73-40E8-8528-B061C8669CB5

Q35505839-93B6F2B9-197A-4530-A480-AE692839271D

Q35505839-B7453681-F733-4D85-A711-25FC275A0FBC

P304

Q35505839-C8B2B60E-51B7-4171-A474-5D1312510B64

P31

Q35505839-9E8680E4-D60E-456E-B163-E65390F87633

P356

Q35505839-0519AD85-E327-4216-B5DB-3B0BAD667C6F

P478

Q35505839-D4AB54A1-A43D-4113-BB8A-46EA24B4982B

P577

Q35505839-7B657F9C-9A8A-4A61-A3E4-932E162A7DB3

P5875

Q35505839-9BED89F3-38EF-4F72-9DCC-B007676811F1

P698

Q35505839-F349AD27-75F1-4EC1-962B-A5FFAE3CDB56

P932

Q35505839-E488DEB8-DC20-480F-8292-CB1E3EFB7FB7

P356

P1433

Pediatric Reports

P1476

Nonmyeloablative, HLA-haploide ...... ansplantation cyclophosphamide

@en

P2093

Ashley Munchel

http://www.w3.org/2001/XMLSchema#string

Chimen Kesserwan

http://www.w3.org/2001/XMLSchema#string

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Heather J Symons

http://www.w3.org/2001/XMLSchema#string

Leo Luznik

http://www.w3.org/2001/XMLSchema#string

Richard J Jones

http://www.w3.org/2001/XMLSchema#string

Yvette L Kasamon

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

High-dose cyclophosphamide for graft-versus-host disease prevention.

Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

Cyclophosphamide-induced immunological tolerance: an overview.

P304

e15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/PR.2011.S2.E15

http://www.w3.org/2001/XMLSchema#string

P478

3 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51766931

http://www.w3.org/2001/XMLSchema#string

P698

22053277

http://www.w3.org/2001/XMLSchema#string

P932

3206539

http://www.w3.org/2001/XMLSchema#string